UroGen Pharma (URGN) Net Income Growth (1y) (2018 - 2026)

UroGen Pharma (URGN) Net Income Growth (1y) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -0.46%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 17,802.13%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 59.59%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -10.08%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 63.48%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 UroGen Pharma 2.07 Bn 1.93 Bn 46.82 Mn 46.23%

Historic Data

Download Data
DateValue
Mar 31, 2026 46.23%
Dec 31, 2025 246.34%
Sep 30, 2025 -40.87%
Jun 30, 2025 -49.51%
Mar 31, 2025 -35.80%
Dec 31, 2024 -1,284.97%
Sep 30, 2024 -8.20%
Jun 30, 2024 -38.39%
Mar 31, 2024 -6.86%
Dec 31, 2023 122.89%
Sep 30, 2023 15.30%
Jun 30, 2023 9.57%
Mar 31, 2023 -6.41%
Dec 31, 2022 -22.67%
Sep 30, 2022 14.50%
Jun 30, 2022 -1.79%
Mar 31, 2022 -9.47%
Dec 31, 2021 -213.86%
Sep 30, 2021 -4.84%
Jun 30, 2021 16.35%